Evidence map›Paper›PMID 23258912›Full record

ArticleDiabetes2013

Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.

Steven F Abcouwer

Abstract readComment
In one paragraph

Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Diabetic retinopathy and systemic factors.Middle East African journal of ophthalmology
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Steven F AbcouwerDepartment of Ophthalmology and Visual Sciences, University of Michigan College of Medicine, Kellogg Eye Center, Ann Arbor, Michigan, USA. sabcouwe@umich.edu

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Tissue-Specific Metabolic Reprogramming in Diabetic ComplicationsDP3DK094292 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C, BURANT, CHARLES F · 2011 to 2011
$5.5M
Targeting the IGF-1 System in Retinal AngiogenesisR01EY007739 · NEI · UNIVERSITY OF FLORIDA · PI ABCOUWER, STEVEN F, GRANT, MARIA BARTOLOMEO · 1995 to 2015
$5.4M
Regulation of Retinal Cell Death in DiabetesR01EY020582 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, GARDNER, THOMAS W. · 2010 to 2018
$4.0M
NEI NIH HHS P30 EY007003NEI NIH HHS P30-EY07003NEI NIH HHS R01 EY007739NEI NIH HHS R01-EY007739NEI NIH HHS R01 EY020582NEI NIH HHS R01-EY020582NIDDK NIH HHS DP3 DK094292NIDDK NIH HHS DP3-DK094292NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDiabetes Mellitus, Type 1Diabetic RetinopathyFenofibrateHypoglycemic AgentsMalePPAR alphaFenofibrateHypoglycemic AgentsPPAR alpha

Identifiers

PMID23258912
PMCPMC3526047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.